Biomarkers in Psoriasis: The Future of Personalised Treatment

Psoriasis is a chronic and complex immune-mediated papulosquamous disease affecting almost 2% of the world population. The interaction between a genetically predisposed individual and environmental triggers leads to a vicious cycle involving autoreactive T cells, dendritic cells, keratinocytes and d...

Full description

Saved in:
Bibliographic Details
Main Authors: Bikash R. Kar (Author), Dharshini Sathishkumar (Author), Sushil Tahiliani (Author), Anchala Parthasarathi (Author), Shekhar Neema (Author), Satyaki Ganguly (Author), K. Venkatachalam (Author), Shrichand G. Parasramani (Author), Haritha Komeravelli (Author), Jaykar Thomas (Author)
Format: Book
Published: Wolters Kluwer Medknow Publications, 2024-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_2d1b75948dae43e28c6073f5a2edb775
042 |a dc 
100 1 0 |a Bikash R. Kar  |e author 
700 1 0 |a Dharshini Sathishkumar  |e author 
700 1 0 |a Sushil Tahiliani  |e author 
700 1 0 |a Anchala Parthasarathi  |e author 
700 1 0 |a Shekhar Neema  |e author 
700 1 0 |a Satyaki Ganguly  |e author 
700 1 0 |a K. Venkatachalam  |e author 
700 1 0 |a Shrichand G. Parasramani  |e author 
700 1 0 |a Haritha Komeravelli  |e author 
700 1 0 |a Jaykar Thomas  |e author 
245 0 0 |a Biomarkers in Psoriasis: The Future of Personalised Treatment 
260 |b Wolters Kluwer Medknow Publications,   |c 2024-06-01T00:00:00Z. 
500 |a 0019-5154 
500 |a 1998-3611 
500 |a 10.4103/ijd.ijd_167_24 
520 |a Psoriasis is a chronic and complex immune-mediated papulosquamous disease affecting almost 2% of the world population. The interaction between a genetically predisposed individual and environmental triggers leads to a vicious cycle involving autoreactive T cells, dendritic cells, keratinocytes and dermal cells. Up to 40% of the psoriasis cases develop disabling psoriatic arthritis and an equal number of patients also tend to develop metabolic syndrome as well as cardiovascular comorbidities; hence, this is no more considered to be a disease limited to skin only. Being a systemic disease, there is an urgent need to develop potential biomarkers for the assessment of disease severity, prediction of outcome of the therapeutic intervention and association with various systemic comorbidities. Diverse genetic markers not only function as predictors of diseases pathogenesis, but also help to predict development of psoriasis and psoriatic arthritis. Personalised medicine is customising the therapeutic needs of a psoriasis patient and improving the outcome as per the hints we receive from the various biomarkers. This review deals with the list of potential biomarkers proposed to be useful in psoriasis, though there is limited data validating their routine use in clinical practice and the progress so far made in the field of precision medicine for psoriasis. 
546 |a EN 
690 |a biomarkers 
690 |a comorbidities 
690 |a genetic markers 
690 |a predictive factors 
690 |a psoriasis 
690 |a Dermatology 
690 |a RL1-803 
655 7 |a article  |2 local 
786 0 |n Indian Journal of Dermatology, Vol 69, Iss 3, Pp 256-263 (2024) 
787 0 |n https://journals.lww.com/ijd/fulltext/2024/05000/biomarkers_in_psoriasis__the_future_of.9.aspx 
787 0 |n https://doaj.org/toc/0019-5154 
787 0 |n https://doaj.org/toc/1998-3611 
856 4 1 |u https://doaj.org/article/2d1b75948dae43e28c6073f5a2edb775  |z Connect to this object online.